Literature DB >> 8383321

Mechanism of action of des-His1-[Glu9]glucagon amide, a peptide antagonist of the glucagon receptor system.

S R Post1, P G Rubinstein, H S Tager.   

Abstract

We have investigated the mechanisms through which des-His1-[Glu9]glucagon amide functions as a peptide antagonist of the glucagon receptor/adenylyl cyclase system. Studies with radiolabeled peptides identified that (i) the antagonist bound to intact hepatocytes according to a single first-order process, whereas the rate of association of glucagon with the same preparation could be described only by the sum of two first-order processes; (ii) the interaction of the antagonist with saponin-permeabilized hepatocytes was not affected by the addition of GTP to the incubation medium or by the elimination of Mg2+, whereas the interaction of glucagon with the same cell preparation was modified significantly by the presence of the nucleotide or by the absence of the divalent metal ion; (iii) the dissociation of antagonist from intact hepatocytes incubated in buffer was complete, whereas that of agonist was not; and (iv) the antagonist bound to intact hepatocytes at steady state according to a single binding isotherm (as did both agonist and antagonist in permeabilized hepatocytes), whereas glucagon bound to the intact cell system with two clearly defined apparent dissociation constants. A model is presented for the mechanism of action of the glucagon antagonist in which the analog binds to glucagon receptors in a Mg(2+)- and GTP-independent fashion and in which resulting ligand-receptor complexes fail to undergo sequential adjustments necessary for the stimulation of adenylyl cyclase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8383321      PMCID: PMC45939          DOI: 10.1073/pnas.90.5.1662

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  The agonist-specific effect of magnesium ion on binding by beta-adrenergic receptors in S49 lymphoma cells. Interaction of GTP and magnesium in adenylate cyclase activation.

Authors:  S J Bird; M E Maguire
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

2.  Slowly reversible binding of catecholamine to a nucleotide-sensitive state of the beta-adrenergic receptor.

Authors:  L T Williams; R J Lefkowitz
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

3.  Magnesium dependence of agonist binding to adenylate cyclase-coupled hormone receptors.

Authors:  L T Williams; D Mullikin; R J Lefkowitz
Journal:  J Biol Chem       Date:  1978-05-10       Impact factor: 5.157

4.  Regulation of beta-adrenergic receptors by guanyl-5'-yl imidodiphosphate and other purine nucleotides.

Authors:  R J Lefkowitz; D Mullikin; M G Caron
Journal:  J Biol Chem       Date:  1976-08-10       Impact factor: 5.157

5.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. II. Comparison between glucagon- and fluoride-stimulated activities.

Authors:  L Birnbaumer; S L Pohl; M Rodbell
Journal:  J Biol Chem       Date:  1971-03-25       Impact factor: 5.157

6.  The glucagon-sensitive adenyl cyclase system in plasma membranes of rat liver. I. Properties.

Authors:  S L Pohl; L Birnbaumer; M Rodbell
Journal:  J Biol Chem       Date:  1971-03-25       Impact factor: 5.157

7.  Identification of adenylate cyclase-coupled beta-adrenergic receptors in frog erythrocytes with (minus)-[3-H] alprenolol.

Authors:  C Mukherjee; M G Caron; M Coverstone; R J Lefkowitz
Journal:  J Biol Chem       Date:  1975-07-10       Impact factor: 5.157

8.  Synthetic peptide antagonists of glucagon.

Authors:  C G Unson; D Andreu; E M Gurzenda; R B Merrifield
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 9.  Structure-conformation-activity studies of glucagon and semi-synthetic glucagon analogs.

Authors:  V J Hruby
Journal:  Mol Cell Biochem       Date:  1982-04-16       Impact factor: 3.396

10.  Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses.

Authors:  R H Unger
Journal:  Diabetes       Date:  1971-12       Impact factor: 9.461

View more
  4 in total

1.  Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.

Authors:  Haruka Okamoto; Katie Cavino; Erqian Na; Elizabeth Krumm; Steven Kim; Panayiotis E Stevis; Joyce Harp; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-31       Impact factor: 11.205

2.  Angptl4 links α-cell proliferation following glucagon receptor inhibition with adipose tissue triglyceride metabolism.

Authors:  Danny Ben-Zvi; Ornella Barrandon; Stephanie Hadley; Barak Blum; Quinn P Peterson; Douglas A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

3.  Glucagon activates Ca2+ and Cl- channels in rat hepatocytes.

Authors:  Edoardo C Aromataris; Michael L Roberts; Greg J Barritt; Grigori Y Rychkov
Journal:  J Physiol       Date:  2006-03-31       Impact factor: 5.182

4.  PKC stimulated by glucagon decreases UT-A1 urea transporter expression in rat IMCD.

Authors:  Yuristella Yano; Adilson C Rodrígues; Ana C de Bragança; Lucia C Andrade; Antonio J Magaldi
Journal:  Pflugers Arch       Date:  2008-05-01       Impact factor: 3.657

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.